Understanding SARS-CoV-2-Mediated Inflammatory Responses: From

Currently there is no effective antiviral therapy for SARS-CoV-2 infection, which frequently leads to fatal inflammatory responses and acute lung injury. Here, we discuss the various mechanisms of SARS-CoV-mediated inflammation. We also assume that SARS-CoV-2 likely shares similar inflammatory responses. Potential therapeutic tools to reduce SARS-CoV-2-induced inflammatory responses include various methods to block FcR activation. In the absence of a proven clinical FcR blocker, the use of intravenous immunoglobulin to block FcR activation may be a viable option for the urgent treatment of pulmonary inflammation to prevent severe lung injury. Such treatment may also be combined with systemic anti-inflammatory drugs or corticosteroids. However, these strategies, as proposed here, remain to be clinically tested for effectiveness.

Inflammatory pathways in COVID‐19: Mechanism and therapeutic interventions - Jiang - 2022 - MedComm - Wiley Online Library

Pulmonary surfactant-mediated inflammatory response against SARS-CoV-2

Autoimmunity and Inflammation

Viruses, Free Full-Text

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

Immune determinants of COVID-19 disease presentation and severity

COVID-19 therapeutics: Challenges and directions for the future

Full article: Short- and potential long-term adverse health outcomes of COVID-19: a rapid review

COVID-19: inflammatory responses, structure-based drug design and potential therapeutics